OCX Oncocyte

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference

NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: .

An archived replay will be available after the call concludes on iMDx’s website within the Investors/Events & Presentations section .

Attendance at 25th Annual Needham Virtual Healthcare Conference

Separately, on April 15th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference, taking place from April 13-16, 2026.

Event: 25th Annual Needham Virtual Healthcare Conference

Presentation Date: April 15, 2026

Format: Virtual fireside chat

Webcast:

iMDx management will also be conducting one-on-one meetings with investors at the conference. Investors wishing to book a meeting are encouraged to reach out to their Needham sales representative.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit  for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:

Alexandra Grossman

LifeSci Advisors LLC

 



EN
20/03/2026

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Atte...

iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference NASHVILLE, Tenn., March 20, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that it will report fourth quarter 2025 financial results after the market closes on Thursday, March 26, 2026. iMDx will host a live Zoom webinar to discuss the company's financial results at 2:00 pm PT / 5:00 pm ET that same day. The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: ...

March 20, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprieta...

Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score New data supports GraftAssure commercialization effortsMulti-center study featured 249 biopsy-matched patientsProprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNAReinforces data presented at World Transplant Congress in 2025 NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the of a new peer-reviewed study demonstrating the potential superiority of the company’s fla...

March 13, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Insight Molecular Diagnostics Completes Key Milestones Advancing Graft...

Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today announced that in February the company completed several major miles...

March 3, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

iMDx Announces $26.0 Million Registered Direct Offering

iMDx Announces $26.0 Million Registered Direct Offering NASHVILLE, Tenn., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (“iMDx” or the “Company”), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale of an aggregate of 4,525,976 shares of its common stock, no par value per share (or pre-funded warrants in lieu thereof) at an offering price of $5.75 per share in a registered direct offering. The purchase price per pre-funded warrant is identical to the purchase price per share o...

February 11, 2026 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized...

IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global tran...

January 13, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch